Lifesaving immunisation: progress made possible by IFFIm
Lifesaving immunisation: progress made possible by IFFIm
29 August 2024
![Credit: Gavi/2023/Benedikt V. Loebell Credit: Gavi/2023/Benedikt V. Loebell](/sites/default/files/2024/RS43223_india-mother-child.jpg)
Credit: Gavi/2023/Benedikt V. Loebell
A child in need of a life-saving vaccine cannot afford to wait. IFFIm employs a frontloading model that enables Gavi to protect people, communities and the world faster by bringing future aid forward to have an immediate impact.
A child in need of a life-saving vaccine cannot afford to wait. IFFIm employs a frontloading model that enables Gavi to protect people, communities and the world faster by bringing future aid forward to have an immediate impact.
IFFlm has catalysed Gavi's life-saving impact by enabling the immunisation of more children, faster. Since 2006, IFFlm has contributed US$ 5.8 billion to bolster Gavi's vaccination programs, representing 17% of Gavi's overall funding. IFFlm has played a transformative role in global health, facilitating Gavi's routine immunisation of over 233 million additional children, contributing to the total 1.1 billion immunised by Gavi. Notably, over 13% of these children - 142 million - were immunised because of IFFlm's ability to frontload donor pledges due years later.
Here are some significant ways IFFIm has made an impact on global health:
1. Scaling up human papillomavirus (HPV) coverage to save girls and women from cervical cancer
IFFIm has been crucial in protecting millions of girls by supporting Gavi’s efforts to eliminate cervical cancer, one of the world’s deadliest diseases. IFFIm provided US$ 130 million to Gavi for HPV programmes, improving the health outlook for millions of mothers, daughters, partners, and sisters. By the end of 2022, these programmes had reached more than 16.3 million girls, averting more than 387,000 deaths. Over the coming years, IFFIm’s support will help Gavi reach over 120 million adolescent girls, with a goal of preventing 1.5 million deaths. These contributions will reduce gender barriers to immunisation and ensure girls grow into strong, healthy women supporting their families and communities.
2. Frontloading pentavalent and cutting vaccine costs
IFFIm was instrumental in reducing the cost of the pentavalent vaccine. In 2007, IFFIm enabled Gavi to make an initial upfront payment of US$ 191 million to vaccine suppliers, encouraging them to increase production and lower prices. An independent evaluation in 2011 found that IFFIm’s funding led to greater competition and reduced prices for pentavalent vaccines. Total IFFIm support for pentavalent vaccines now exceeds US$ 1.5 billion, with the average cost of fully immunising a child with pentavalent dropping from US$ 8.95 in 2010 to US$ 2.81 in 2023. By the end of 2022, over 705 million children in 73 countries had been immunised with a pentavalent vaccine with Gavi support. These children can now look forward to a healthy future.
![IFFIm's impact on Gavi's mission](/sites/default/files/2024/chart-iffim-gavi-impact.jpg)
3. Enabling Gavi’s Ebola response
IFFIm significantly boosted Gavi’s ability to respond swiftly to emergencies, notably during the 2014 Ebola crisis. IFFIm’s flexibility to provide funding at scale allowed Gavi to commit US$ 300 million to a comprehensive Ebola response, including the procurement of hundreds of millions of vaccine doses. This proactive approach spurred vaccine development, advanced trials, and the creation of a stockpile of 300,000 investigational doses for combating Ebola outbreaks in the Democratic Republic of the Congo (DRC) during 2018 and 2019. By protecting more than 206,000 people from Ebola, IFFIm helped halt the spread of this highly contagious and fatal disease, saving countless lives
4. Strengthening country health systems
Strong health systems are crucial not only for delivering life-saving vaccines but also for preventing disease outbreaks. IFFIm kickstarted Gavi’s health system strengthening investments (HSS) in 40 countries, accounting for nearly 84% of Gavi’s initial funding during the first two years. Vaccinating a child connects families with healthcare systems, especially in hard-to-reach places. IFFIm’s flexible funding has consistently enabled lower income countries to enhance and maintain the essential health systems that communities rely upon. By December 2022, IFFIm had provided nearly 10% of its funding to Gavi for HSS, totalling close to US$ 500 million.
5. Extending IFFIm’s invaluable frontloading capabilities as a critical pandemic response tool
IFFIm emerged as one of the earliest funding sources to support Gavi’s global pandemic response, frontloading over 90%, or US$ 975 million, of donor pledges for the COVAX Advance Market Commitment (COVAX AMC) alongside an additional US$ 206 million for CEPI’s C19 vaccine research and development. This feat was only possible because IFFIm had available funding capacity supported by other IFFIm grants. IFFIm was able to frontload grants notionally allocated for the COVAX AMC providing US$ 400 million in January 2021, within a month of the grant signature.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Lifesaving immunisation: progress made possible by IFFIm
29 August 2024
Strengthening Gavi's replenishment with IFFIm
29 August 2024
IFFIm Board of Directors welcomes three new members
01 July 2024